Earnings Summary

Black Diamond Therapeutics’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Black Diamond Therapeutics has generated NaN% jump in its revenue since last 3-months.

Black Diamond Therapeutics’s net profit fell -13.83% since last year same period to $-19.41Mn in the Q4 2023. On a quarterly growth basis, Black Diamond Therapeutics has generated 15.64% jump in its net profits since last 3-months.

Black Diamond Therapeutics’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Black Diamond Therapeutics has generated NaN% jump in its net profit margins since last 3-months.

Black Diamond Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a 8.51% jump from last quarter’s estimates.

Black Diamond Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.43.

Black Diamond Therapeutics’s earning per share (EPS) jumped 42.37% since last year same period to -0.34 in the Q4 2023. This indicates that the Black Diamond Therapeutics has generated 42.37% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Black Diamond Therapeutics’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Black Diamond Therapeutics’s return on equity (ROE) stands at -0.71.